Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 2
1991 4
1992 3
1993 2
1996 1
1997 1
1998 1
1999 2
2000 1
2002 1
2003 1
2004 2
2005 4
2006 2
2007 1
2008 3
2009 1
2010 3
2011 4
2012 2
2013 2
2014 6
2015 8
2016 3
2017 7
2018 3
2019 8
2020 4
2021 8
2022 5
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Mayer RJ, et al. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. N Engl J Med. 2015. PMID: 25970050 Free article. Clinical Trial.
PLA2G12A as a Novel Biomarker for Colorectal Cancer with Prognostic Relevance.
Parisi E, Hidalgo I, Montal R, Pallisé O, Tarragona J, Sorolla A, Novell A, Campbell K, Sorolla MA, Casali A, Salud A. Parisi E, et al. Among authors: salud a. Int J Mol Sci. 2023 Jun 30;24(13):10889. doi: 10.3390/ijms241310889. Int J Mol Sci. 2023. PMID: 37446068 Free PMC article.
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.
Toledano-Fonseca M, Gómez-España MA, Élez E, Grávalos C, García-Alfonso P, Rodríguez R, Losa F, Alés Díaz I, Graña B, Valladares-Ayerbes M, García-Ortiz MV, Polo E, Salgado M, Rivera F, Safont MJ, Salud A, Ruiz-Casado A, Tabernero JM, Riesco MC, Rodríguez-Ariza A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Toledano-Fonseca M, et al. Among authors: salud a. Biomed Pharmacother. 2023 Mar;159:114272. doi: 10.1016/j.biopha.2023.114272. Epub 2023 Jan 25. Biomed Pharmacother. 2023. PMID: 36706629 Free article.
Breakthrough cancer pain: review and calls to action to improve its management.
Camps Herrero C, Batista N, Díaz Fernández N, Escobar Álvarez Y, Gonzalo Gómez A, Isla Casado D, Salud A, Terrasa Pons J, Guillem Porta V. Camps Herrero C, et al. Among authors: salud a. Clin Transl Oncol. 2020 Aug;22(8):1216-1226. doi: 10.1007/s12094-019-02268-8. Epub 2020 Jan 30. Clin Transl Oncol. 2020. PMID: 32002739 Review.
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402.
Pesántez D, Ten Hoorn S, Machado I, García-Albéniz X, Rodríguez-Salas N, Heredia-Soto V, Viñal D, Pericay C, García-Carbonero R, Losa F, Alonso V, Vera R, Feliu Batlle J, Gallego J, Salud A, Nogué M, Layos L, Montagut C, Capdevila J, Vermeulen L, Maurel J, Fernandez-Martos C. Pesántez D, et al. Among authors: salud a. J Natl Cancer Inst. 2023 Dec 6;115(12):1497-1505. doi: 10.1093/jnci/djad120. J Natl Cancer Inst. 2023. PMID: 37405857 Clinical Trial.
96 results